Bain, others invest in Nimbus Therapeutics' $125M round. Here's what the CEO had to say.
Nimbus Therapeutics last made headlines in 2016, when the Cambridge-based company sold a drug for the liver disease NASH to Gilead Sciences (Nasdaq: GILD) for a clean $1.2 billion — including $400 million up front. Since then, the company has quietly shifted its focus to autoimmune disease drugs, targeting the skin disorder psoriasis and certain cancers. Nimbus got a boost to those efforts on Monday.
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Rowan Walrath Source Type: news
More News: American Health | Autoimmune Disease | Cancer | Cancer & Oncology | Health Management | Liver | Liver Disease | Psoriasis | Skin | Urology & Nephrology